Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Operations: 2017-2024

Historic Cash from Operations for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $25.7 million.

  • Kiniksa Pharmaceuticals International's Cash from Operations rose 1606.13% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.9 million, marking a year-over-year increase of 814.81%. This contributed to the annual value of $25.7 million for FY2024, which is 93.14% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Cash from Operations of $25.7 million as of FY2024, which was up 93.14% from $13.3 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cash from Operations ranged from a high of $25.7 million in FY2024 and a low of -$136.5 million during FY2020.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Cash from Operations had a median value of $13.3 million in 2023 and averaged $14.9 million.
  • Data for Kiniksa Pharmaceuticals International's Cash from Operations shows a peak YoY spiked of 129.05% (in 2023) over the last 5 years.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cash from Operations (Yearly) stood at -$136.5 million in 2020, then grew by 7.50% to -$126.3 million in 2021, then surged by 104.60% to $5.8 million in 2022, then surged by 129.05% to $13.3 million in 2023, then spiked by 93.14% to $25.7 million in 2024.